HepC Micro-elimination on MSM and TGW Population.

HepC Micro-elimination on MSM Comunity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06847958

Enrollment

13161

Registered

2025-02-26

Start date

2021-08-23

Completion date

2023-09-30

Last updated

2025-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drugs of Abuse, Hepatitis C, PrEP

Keywords

MSM, TGW, PrEP, Hepatitis C Transmision, micro-elimination

Brief summary

This is an observational study, in which a single visit will be carried out, which includes a questionnaire on sexual habits and in which the possibility of carrying out a screening for Hepatitis C will be offered. Depending on the score obtained in the questionnaire, the screening will be carried out using a rapid serology test or viral load. During the first year, a SCORE will be developed to classify the risk of positive results. This SCORE will be used during phase 2 to offer users of the centres a targeted screening based on the Pre-test score.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. All BCN Checkpoint and BCN PreP·Point clients. 2. 18 years and older. 3. HIV uninfected or diagnosticated in the center in the last 7 days prior to the study inclusion. 4. Men that have sex with men or transgender women. 5. Signature of written consent form. 6. Ability to comply with the requirements of the study protocol.

Exclusion criteria

1. Knowledge of HIV infection from more than 7 days 2. Knowledge of active HCV infection

Design outcomes

Primary

Measure	Time frame	Description
Hepatitis C active infection	August 2021 o September 2023	Confirmed Hepatitis C active infection

Countries

Spain

Outcome results